Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2021
Reporting Period: Specific event date (August 6, 2021)
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a legal event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports a material legal development concerning a wrongful death complaint filed in April 2017 against the Company and other defendants, including its former subsidiary Biostage, Inc. The complaint alleges terminal injuries caused by products (a synthetic trachea scaffold and bioreactors) used in surgeries in Europe in 2012 and 2013.
- Previous Status: Sanctions had been entered against the defendants.
- Current Status: On August 6, 2021, the Suffolk Superior Court issued a ruling in the Company's favor, vacating the sanctions.
- Next Steps: The case will now proceed on the merits.
Outlook, Risks, and Management Commentary
Management Commentary: The Company states it will continue to oppose the lawsuit vigorously. Management believes the claims are without merit, though they acknowledge there can be no assurance of prevailing.
Risks and Contingencies: The lawsuit seeks an unspecified amount of damages. The outcome remains uncertain as the case proceeds to the merits phase.
Key Facts for Investor Verification
- Sanctions previously entered against the Company in the 2017 wrongful death lawsuit have been vacated by the court.
- The lawsuit involves products from a former subsidiary (Biostage, Inc.) spun off in 2013.
- The damages sought in the complaint are unspecified.
- The Company maintains the claims are without merit but faces ongoing litigation risk.